SLC5A2 and hydrops fetalis: Drugs that target the RAAS (ARBs and ACEIs) [32] and SGLT2 inhibitors [33] are recommended for patients with HF and diabetes, as well as for patients with HF and especially type 2 diabetes, respectively.